(Q37131233)

18 August 2017

1 reference

title

Symptomatic treatment of Huntington disease (English)

1 reference

18 August 2017

0 references

2

Joseph Jankovic

1 reference

18 August 2017

Octavian R Adam

1

1 reference

18 August 2017

1 April 2008

1 reference

18 August 2017

1 reference

18 August 2017

5

1 reference

18 August 2017

2

1 reference

18 August 2017

181-197

1 reference

https://scigraph.springernature.com/pub.10.1016/j.nurt.2008.01.008

18 August 2017

0 references

cites work

Suppression of neurodegeneration and increased neurotransmission caused by expanded full-length huntingtin accumulating in the cytoplasm

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084162

Huntington's disease phenocopy syndromes

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084162

Dopaminergic signaling and striatal neurodegeneration in Huntington's disease

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084162

A systematic review of the treatment studies in Huntington's disease since 1990.

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084162

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084162

Is history of depression a contraindication to treatment with tetrabenazine?

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084162

Pharmacological management of Huntington's disease: an evidence-based review

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084162

Effect of fetal neural transplants in patients with Huntington's disease 6 years after surgery: a long-term follow-up study

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084162

Dose-dependent improvement of myoclonic hyperkinesia due to Valproic acid in eight Huntington's Disease patients: a case series.

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084162

Tetrabenazine in the treatment of hyperkinetic movement disorders

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084162

Pharmaceutical, cellular and genetic therapies for Huntington's disease

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084162

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084162

Modern antipsychotic drugs: a critical overview

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084162

Tetrabenazine treatment in movement disorders

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084162

Short-term effects of olanzapine in Huntington disease.

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084162

Fluoxetine in the treatment of Huntington's disease

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084162

Transplanted fetal striatum in Huntington's disease: phenotypic development and lack of pathology

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084162

Inhibition of neuronal hypersynchrony in vitro differentiates levetiracetam from classical antiepileptic drugs

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084162

Brain SPECT imaging in Huntington's disease before and after therapy with olanzapine. Case report

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084162

Late onset levodopa responsive Huntington's disease with minimal chorea masquerading as Parkinson plus syndrome

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084162

Influence of lamotrigine on progression of early Huntington disease: a randomized clinical trial

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084162

Levodopa responsive parkinsonism in an adult with Huntington's disease

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084162

Clozapine versus placebo in Huntington's disease: a double blind randomised comparative study

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084162

A double blind trial of sulpiride in Huntington's disease and tardive dyskinesia

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084162

Tetrabenazine therapy of dystonia, chorea, tics, and other dyskinesias

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084162

The mode of action of tetrabenazine on peripheral noradrenergic nerves

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084162

A Double Blind Trial of Lithium Carbonate and Haloperidol in Huntington's Chorea

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084162

Tetrabenazine and movement disorders

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084162

The trial use of clozapine for abnormal involuntary movement disorders

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084162

Sodium valproate in Huntington's disease

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084162

Valproate Sodium in Huntington Chorea

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084162

Rate of functional decline in Huntington's disease. Huntington Study Group

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084162

A controlled clinical trial of baclofen as protective therapy in early Huntington's disease

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084162

Cortical reflex myoclonus in adult onset Huntington's disease

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084162

Olanzapine for Huntington's disease: an open label study

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084162

Riluzole in Huntington's disease (HD): an open label study with one year follow up.

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084162

Riluzole therapy in Huntington's disease (HD).

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084162

ECT in genetically confirmed Huntington's disease

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084162

Sertraline in the treatment of severe aggressiveness in Huntington's disease

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084162

Clozapine in Huntington's chorea

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084162

Tiapride in the treatment of Huntington's chorea

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084162

Treatment of hyperkinetic movement disorders with tetrabenazine: a double-blind crossover study

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084162

Tiapride versus placebo: a double-blind comparative study in the management of Huntington's chorea

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084162

Letter: Treatment of Huntington's chorea with tetrabenazine

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084162

A double-blind trial of tetrabenazine, thiopropazate, and placebo in patients with chorea

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084162

The gait abnormality of Huntington's disease

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084162

Neuroleptic malignant syndrome related to tetrabenazine introduction and haloperidol discontinuation in Huntington's disease

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084162

Action myoclonus in adult Huntington's disease

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084162

Autopsy-proven Huntington's disease with 29 trinucleotide repeats

27 June 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2008.01.008

Functional decline in Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2008.01.008

Effect of tetrabenazine on extrapyramidal movement disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2008.01.008

Tetrabenazine treatment for Huntington's disease-associated chorea

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2008.01.008

Tetrabenazine-induced depletion of brain monoamines: characterization and interaction with selected antidepressants.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2008.01.008

Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2008.01.008

Short-term effects of tetrabenazine on chorea associated with Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2008.01.008

Tetrabenazine as a cause of neuroleptic malignant syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2008.01.008

Clozapine treatment of psychiatric symptoms resistant to neuroleptic treatment in patients with Huntington's chorea

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2008.01.008

Olanzapine in Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2008.01.008

Functional and motor response to low dose olanzapine in Huntington's disease: case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2008.01.008

High-dose olanzapine in Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2008.01.008

Olanzapine and Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2008.01.008

Improvement of Huntington's disease with olanzapine and valproate

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2008.01.008

The use of olanzapine for movement disorder in Huntington's disease: a first case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2008.01.008

Risperidone in chorea and psychosis of Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2008.01.008

Effectiveness of risperidone in Huntington chorea patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2008.01.008

Risperidone in treatment of choreoathetosis of Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2008.01.008

Quetiapine in the treatment of behavioral disturbances in patients with Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2008.01.008

Quetiapine in Huntington's disease: a first case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2008.01.008

Ziprasidone in Huntington's disease: the first case reports

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2008.01.008

Huntington's disease: a randomized, controlled trial using the NMDA-antagonist amantadine

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2008.01.008

IV amantadine improves chorea in Huntington's disease: an acute randomized, controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2008.01.008

A randomized trial of amantadine in Huntington disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2008.01.008

A controlled trial of remacemide hydrochloride in Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2008.01.008

Riluzole in Huntington's disease: a 3-year, randomized controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2008.01.008

Dosage effects of riluzole in Huntington's disease: a multicenter placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2008.01.008

Delayed amnesic syndrome after riluzole autointoxication in Huntington disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2008.01.008

Intoxication with riluzole in Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2008.01.008

Adult onset myoclonic Huntington's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2008.01.008

Cortical myoclonus in Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2008.01.008

Open-label pilot study of levetiracetam (Keppra) for the treatment of chorea in Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2008.01.008

Efficacy of levetiracetam in Huntington disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2008.01.008

Levetiracetam-induced parkinsonism in a Huntington disease patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2008.01.008

Pramipexole ameliorates neurologic and psychiatric symptoms in a Westphal variant of Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2008.01.008

Effect of donepezil on motor and cognitive function in Huntington disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2008.01.008

Donepezil for Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2008.01.008

Effects of rivastigmine on motor and cognitive impairment in Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2008.01.008

Treatment of Huntington's disease with galantamine

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2008.01.008

A controlled trial of fluoxetine in nondepressed patients with Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2008.01.008

L-Deprenyl augmentation of fluoxetine in a patient with Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2008.01.008

Mirtazapine in suicidal Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2008.01.008

Bilateral globus pallidus stimulation for Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2008.01.008

Bilateral stimulation of the globus pallidus internus to treat choreathetosis in Huntington's disease: technical case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2008.01.008

Neuropsychological functioning following fetal striatal transplantation in Huntington's chorea: three case presentations

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2008.01.008

Safety of intrastriatal neurotransplantation for Huntington's disease patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2008.01.008

Safety and tolerability assessment of intrastriatal neural allografts in five patients with Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2008.01.008

Motor and cognitive improvements in patients with Huntington's disease after neural transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2008.01.008

Bilateral human fetal striatal transplantation in Huntington's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2008.01.008

Neural transplantation in Huntington disease: long-term grafts in two patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2008.01.008

Bruxism in Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2008.01.008

A study of chorea after tetrabenazine withdrawal in patients with Huntington disease

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084162

Clinical experience with risperidone and memantine in the treatment of Huntington's disease.

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084162

Cabergoline in Huntington's disease: the first case report

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084162

The N-methyl-D-aspartate antagonist memantine retards progression of Huntington's disease.

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084162

Quetiapine in the management of psychosis secondary to huntington's disease: a case report

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084162

A case of obsessive symptoms in Huntington's disease

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084162

Treatment of Huntington's chorea with tetrabenazine (Nitoman).

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084162

Fluoxetine-induced exacerbation of chorea in Huntington's disease? A case report

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084162

Olanzapine improves chorea in patients with Huntington's disease

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084162

Obsessive compulsive disorder in huntington disease: a case of isolated obsessions successfully treated with sertraline.

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084162

A randomized, placebo-controlled trial of coenzyme Q10 and remacemide in Huntington's disease

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084162

Efficacy of clozapine in the course of Huntington chorea: apropos of a clinical case

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084162

Use of risperidone in psychosis associated with Huntington's disease

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084162

Psychiatric and neuropsychological abnormalities in Huntington's disease: a case study

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084162

Fetal striatal homotransplantation for Huntington's disease: first two case reports.

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084162

Huntington disease: tetrabenazine compared to haloperidol in the reduction of involuntary movements

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084162

Unified Huntington's disease rating scale: Reliability and consistency

3 September 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2008.01.008

IV amantadine improves chorea in Huntington's disease: an acute randomized, controlled study

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/18394562

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Levetiracetam-induced Parkinsonism in a Huntington disease patient

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/18394562

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1016/J.NURT.2008.01.008

1 reference

PMC publication ID

5084162

Dimensions Publication ID

18 August 2017

0 references

1 reference

PMC publication ID

5084162

18 August 2017

PubMed publication ID

18394562

1 reference

PMC publication ID

5084162